Detalhe da pesquisa
1.
Evaluation of a multiphasic parasite clearance profile after treatment of experimental human infection with the investigational anti-malarial M5717 using segmented mixed effect models.
Malar J
; 22(1): 199, 2023 Jun 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-37381013
2.
Reproducibility of malaria sporozoite challenge model in humans for evaluating efficacy of vaccines and drugs: a systematic review.
BMC Infect Dis
; 21(1): 1274, 2021 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-34930178
3.
Efficacy, safety, and palatability of arpraziquantel (L-praziquantel) orodispersible tablets in children aged 3 months to 6 years infected with Schistosoma in Côte d'Ivoire and Kenya: an open-label, partly randomised, phase 3 trial.
Lancet Infect Dis
; 23(7): 867-876, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36893784
4.
Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands.
Lancet Infect Dis
; 23(10): 1164-1174, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37414066
5.
Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
Lancet Infect Dis
; 21(12): 1713-1724, 2021 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-34715032